Skip to content
lifestyle.cleanweb.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NeOnc Technologies Holdings, Inc.
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
August 10, 2026
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 10, 2026
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
July 27, 2026
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
May 18, 2026
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
May 5, 2026
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
May 3, 2026
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
May 1, 2026
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
April 29, 2026
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
March 4, 2026
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
February 27, 2026